Analyzing the Phase 3 LUNA 3 Study Results for Wayrilz (rilzabrutinib) in Immune Thrombocytopenia from Sanofi

Scheduled for:Dec 30, 2025 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A hematologist specializing in immune thrombocytopenia and rare autoimmune hematologic disorders, with significant experience in clinical trials involving BTK inhibitors and platelet modulation therapies. The expert should also be knowledgeable about the evolving treatment landscape for ITP and quality-of-life outcomes in chronic immune disorders.

Interview Goal

The interview aims to explore the clinical significance of the FDA approval of Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor for treating persistent and chronic immune thrombocytopenia (ITP). The discussion will focus on the pivotal Phase 3 LUNA 3 study, its efficacy and safety outcomes, the therapy’s novel multi-immune modulation mechanism, patient quality of life improvements, and its potential to reshape the treatment landscape for ITP and related rare immune-mediated diseases.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.